Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Surgical Endoscopy
Erschienen in: Surgical Endoscopy 8/2009

01.08.2009

Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20–34

verfasst von: Aureo Ludovico DePaula, A. L. V. Macedo, V. Schraibman, B. R. Mota, S. Vencio

Erschienen in: Surgical Endoscopy | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

A group of patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) 20–34 kg/m2 were submitted to laparoscopic interposition of a segment of ileum into the proximal jejunum or into the proximal duodenum associated to a sleeve gastrectomy. The objective of this study is to evaluate the hormonal changes in the pre- and postoperative period.

Materials and methods

Hormonal evaluation was done in 58 patients operated between April 2005 and July 2006. Mean age was 51.4 years (40–66 years). Mean BMI was 28.2 (20–34.8) kg/m2. All patients had had the diagnosis of T2DM for at least 3 years. Mean duration of T2DM was 9.6 years (3–22 years). Two techniques were performed, consisting of different combinations of ileal interposition (II) associated to a sleeve gastrectomy (SG). The following hormones were assayed in the pre- and postoperative period (mean 16 months) at the baseline and following specific food stimulation (30, 60, 120 min): glucogen-like protein 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), insulin, glucagon, C-peptide, amylin, colecystokinin (CCK), pancreatic polypeptide (PPP), somatostatin, peptide YY (PYY), ghrelin, adiponectin, resistin, leptin, and interleukin-6 (IL-6).

Results

Thirty patients had II associated to sleeve gastrectomy (II-SG) and 28 had II with diverted sleeve gastrectomy (II-DSG). GLP1 exhibited an important rise following the two operations, especially after II-DSG (p < 0.001). GIP also exhibited an important rise, with both II-SG and II-DSG being equally effective (p < 0.001). Insulin and amylin showed a significant rise at 30 min. Glucagon decreased slightly. CCK measurements were very low after II-DSG. PPP was also slightly altered by the II-DSG. PYY showed an important increase with both operations (p < 0.001). Ghrelin showed a significant decrease following the two operations (p < 0.001).Somatostatin and IL-6 were not affected (p = 0.632). Both leptin and resistin blood levels decreased. Adiponectin showed a slight increase. Mean postoperative follow-up was 19.2 months. Both II-SG and II-DSG were effective in achieving adequate glycemic control (91.2%).

Conclusions

There was a significant hormonal change following laparoscopic ileal interposition. These alterations may explain the promising good results associated to these operations for the treatment of T2DM in the nonmorbidly obese population.
Literatur
1.
2.
Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C (2005) Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 31:233–242PubMedCrossRef
3.
Vilsboll T, Krarup T, Madsbad S, Holst JJ (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111–1119PubMedCrossRef
4.
Knopp FI, Vilsboll T, Hojberg PV, Lasrsen S, Madsbad S, Holst JJ, Krarup T (2007) The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regul Pept 144:123–130CrossRef
5.
Heijboer AC, Pijil H, Van den Hoek AM, Havekes LM, Romijn JA, Corssmit EPM (2006) Gut–brain axis: regulation of glucose metabolism. J Neuroendocrinol 18:883–894PubMedCrossRef
6.
DePaula AL, Macedo ALV, Rassi N, Machado CA, Schraibman V, Silva LQ, Halpern H (2008) Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc 22:706–716PubMedCrossRef
7.
Kahn SE (2001) Beta-cell failure: causes and consequences. Int J Clin Pract 123:13–18
8.
Luzi L, DeFronzo RA (1989) Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 257:E241–E246PubMed
9.
Rask E, Olsson T, Soderberg S, Holst JJ, Tura A, Pacini G, Ahren B (2004) Insulin secretion and incretin hormones after oral glucose in nonobese subjects with impaired glucose tolerance. Metabolism 53:624–631PubMedCrossRef
10.
Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22:283–291PubMedCrossRef
11.
Ahrén B, Host JJ, Mari A (2003) Characterization of GLP-1 effects on β-cell function after meal ingestion in humans. Diabetes Care 26:2860–2864PubMedCrossRef
12.
Vilsboll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide regardless of etiology and phenotype. J Clin Endocrinol Metab 88:4897–4903PubMedCrossRef
13.
Theodorakis MJ, Carlson O, Muller DC, Egan JM (2004) Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 27:1692–1698PubMedCrossRef
14.
Zhou H, Yamada Y, Tsukiyama K, Miyawaki K, Hosokawa M, Nagashima K, Toyoda K, Naitoh R, Mizunoya W, Fushiki T, Kadowaki T, Seino Y (2005) Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochem Biophys Res Commun 335:937–942PubMedCrossRef
15.
Yach D, Stuckler D, Brownell KD (2006) Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 12:62–66PubMedCrossRef
16.
17.
Gauna C, Meyler FM, Janssen JA, Delhanty PJ, Abribat T, van Koetsveld P, Hofland LJ, Broglio F, Ghigo E, van der Lely AJ (2004) Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 89:5035–5042PubMedCrossRef
18.
Lippl F, Kircher F, Erdmann J, Allescher HD, Schusdziarra V (2004) Effect of GIP, GLP-1, insulin and gastrin on ghrelin release in the isolated rat stomach. Regul Pept 119:93–98PubMedCrossRef
19.
Dezaki K, Hosoda H, Kakei M, Hashiguchi S, Watanabe M, Kangawa K, Yada T (2004) Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2 signaling in β-cells. Diabetes 53:3142–3151PubMedCrossRef
20.
Kjems LL, Holst JJ, Volund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380–386PubMedCrossRef
21.
Drucker DJ (2003) Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929–2940PubMedCrossRef
22.
Irwin N, Gault VA, Green BD, Greer B, McCluskey JT, Harriott P, O’Harte FP, Flatt PR (2004) Effects of short-term chemical ablation of GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biol Chem 385:845–852PubMedCrossRef
23.
Gault VA, Irwin N, Green BD, Mccluskey JT, Greer B, Bailey CJ, Harriott P, O’Harte FPM, Flatt PR (2005) Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro 3) GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54:2436–2446PubMedCrossRef
24.
Ferrannnini E, Cobeli C (1987) The kinetics of insulin in man. I. General aspects. Diab Metab Rev 3:335–363CrossRef
25.
Ferrannini E (1998) Insulin resistance versus insulin deficiency in non-insulin dependent diabetes mellitus: problems and prospects. Endocr Rev 19:477–490PubMedCrossRef
26.
Ferrannini E, Mari A (2004) Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 47:943–956PubMedCrossRef
27.
Kahn SE (2001) The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047–4058PubMedCrossRef
28.
Gromada J, Franklin I, Wollheim CB (2007) α-Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84–116PubMedCrossRef
29.
Dunning BE, Foley JE, Ahren B (2005) α-Cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 48:1700–1713PubMedCrossRef
30.
Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza R (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053–4059PubMedCrossRef
31.
Esler PW, Rudolph J, Claus TH, Tang W, Barucc N, Brown SU, Bullock W, Daly M, DeCarr L, Li Y, Milardo L, Molstad D, Zhu J, Gardell SJ, Livingston JN, Sweet L (2007) Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 148:5175–5185PubMedCrossRef
32.
Le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, Wynne KJ, Kent A, Vincent RP, Gardiner J, Ghatei MA, Bloom SR (2006) Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147:3–8PubMedCrossRef
33.
Borg CM, Le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJB (2006) Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 93:210–215PubMedCrossRef
34.
Hoppener JWM, Ahren B, Lips CJM (2000) Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343:411–419PubMedCrossRef
35.
Philips LK, Horowitz M (2006) Amylin. Curr Opin Endocrinol Diabetes 13:191–198CrossRef
36.
Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, Fujino MA, Niijima A, Meguid MM, Kasuga M (2003) Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124:1325–1336PubMedCrossRef
37.
Kojima S, Ueno N, Asakawa A, Sagiyama K, Naruo T, Mizuno S, Inui A (2007) A role for pancreatic polypeptide in feeding and body weight regulation. Peptides 28:459–463PubMedCrossRef
38.
Yamomoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, Okazaki Y, Ishii T, Nishikai K, Saruta T (2002) Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 103:137–142
39.
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endeocrinol Metab 85:1930–1935CrossRef
40.
Shetty GK, Economides ES, Horton ES, Mantzoros CS, Veves A (2004) Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27:2450–2457PubMedCrossRef
41.
DePaula, AL, Macedo AL, Rassi N, Vencio S, Machado CA, Mota BR, Silva LQ, Halpern A, Schraibman V (2008) Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus. Surg Endosc [Epub ahead of print]
42.
Anini Y, Brubaker PL (2003) Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 52:252–259PubMedCrossRef
43.
Kieffer TJ, Habener JF (2000) The adipoinsular axis: effects of leptin on pancreatic β-cells. Am J Physiol Endocrinol Metab 278:E1–E14PubMed
44.
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312PubMedCrossRef
45.
Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahina RS (2004) Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 53:1671–1679PubMedCrossRef
46.
Hansotia T, Drucker DJ (2005) GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 128:125–134PubMedCrossRef
Metadaten
Titel
Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20–34
verfasst von
Aureo Ludovico DePaula
A. L. V. Macedo
V. Schraibman
B. R. Mota
S. Vencio
Publikationsdatum
01.08.2009
Verlag
Springer-Verlag
Erschienen in
Surgical Endoscopy / Ausgabe 8/2009
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-008-0168-6

Weitere Artikel der Ausgabe 8/2009

Surgical Endoscopy 8/2009 Zur Ausgabe

OriginalPaper

Risk factors for cholecystectomy in patients with gallbladder stones after endoscopic clearance of common bile duct stones

OriginalPaper

Antegrade stenting in laparoscopic pyeloplasty: feasibility of the technique and time required for stent insertion

OriginalPaper

Laparoscopically assisted ileocolectomy in patients with Crohn’s disease: a study of 50 consecutive patients

OriginalPaper

Preliminary results with a training program for thoracoscopic atrial fibrillation therapy

OriginalPaper

Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease using multiple Plicator implants: 12-month multicenter study results

Review

What is going on in augmented reality simulation in laparoscopic surgery?

Neu im Fachgebiet Chirurgie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs
CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs
CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs
CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.